SOPH Stock Forecast & Price Target

Sophia Genetics is well positioned because its cloud-based, pay-per-analysis SaaS model converts rising clinical data complexity into recurring revenue, with 2025 revenue of $77.3M and 2026 guidance of $92M–$96M, while adjusted gross margin remained strong at 72.1% in 2Q26. Its moat is reinforced by a compounding global network spanning about 1,000 hospitals and laboratories across 75 countries and more than 2.5M genomic profiles, which improves algorithms, retention, and cross-sell opportunities as adoption deepens. The outlook is further supported by accelerating U.S. expansion, marquee relationships with Memorial Sloan Kettering and MD Anderson, and a returning biopharma contribution led by AstraZeneca and other large partners, all of which strengthen visibility toward positive adjusted EBITDA in 2H27.

Sophia Genetics is facing a weak fundamental outlook because its 2024 growth was only 4% even as volumes rose 11%, implying a 6-7% decline in revenue per analysis and signaling pricing or mix pressure, especially from biopharma headwinds. The bear case also assumes BioPharma DDM remains only about 5% of revenue from 2026 to 2033, with peak total revenue limited to $441M and gross margins stuck near 70%, suggesting muted operating leverage and limited upside from a key growth area. On top of that, the company is still not profitable and faces commercial execution, competition, cybersecurity, legal, and dilution risks, any of which could restrain adoption, increase costs, and force further equity financing.